Times are shown in your local time zone GMT
Ad-blocker Detected - Your browser has an ad-blocker enabled, please disable it to ensure your attendance is not impacted, such as CPD tracking (if relevant). For technical help, contact Support.
Dr Louise Segan
Baker Heart and Diabetes Institute
Professional Bio
Dr Louise Segan is a consultant cardiologist and clinical electrophysiology fellow at the Alfred Hospital. She is undertaking a full-time PhD in cardiac electrophysiology through the Baker Heart and Diabetes Institute and the University of Melbourne under the supervision of Professor Peter Kistler, Professor Jon Kaman and A/Prof Sandeep Prabhu.
Dr Segan is supported by an NHMRC and National Heart Foundation scholarship. Her research focuses on optimising outcomes in patients with atrial fibrillation (AF) and heart failure well as focusing on improving recognition of the important role of lifestyle modification in AF management.
She is coordinating two ANZCTR registered clinical trials. The first, CAMERA-MRI II randomised study of early catheter ablation versus medical rate control in AF and HF with CMR-detected myocardial fibrosis, began recruitment in late 2020 and is nearing completion. The WITHDRAW-AF randomised study explores the safety and feasibility of staged withdrawal of neurohormonal therapies in patients with rhythm-controlled AF and recovered AF mediated cardiomyopathy, for which recruitment is currently underway.
Dr Segan is the recipient of the CSANZ 2022 prevention prize, the 2022 Baker Symposium Rod Andrews Prize and the inaugural 2022 ISHR Australasia ECIC Carer Award.
Dr Segan is supported by an NHMRC and National Heart Foundation scholarship. Her research focuses on optimising outcomes in patients with atrial fibrillation (AF) and heart failure well as focusing on improving recognition of the important role of lifestyle modification in AF management.
She is coordinating two ANZCTR registered clinical trials. The first, CAMERA-MRI II randomised study of early catheter ablation versus medical rate control in AF and HF with CMR-detected myocardial fibrosis, began recruitment in late 2020 and is nearing completion. The WITHDRAW-AF randomised study explores the safety and feasibility of staged withdrawal of neurohormonal therapies in patients with rhythm-controlled AF and recovered AF mediated cardiomyopathy, for which recruitment is currently underway.
Dr Segan is the recipient of the CSANZ 2022 prevention prize, the 2022 Baker Symposium Rod Andrews Prize and the inaugural 2022 ISHR Australasia ECIC Carer Award.